false
--12-31
0001739614
0001739614
2024-05-30
2024-05-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 30, 2024
Inhibrx, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
001-39452 |
82-4257312 |
(State
or other jurisdiction of incorporation) |
(Commission
File Number) |
(IRS
Employer Identification No.) |
11025 N. Torrey Pines Road, Suite 200
La Jolla, CA 92037
(Address of principal executive offices, including
zip code)
(858) 795-4220
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
symbol |
Name
of each exchange on which registered |
Common Stock, par value $0.0001 per share |
INBX |
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Introductory Note
On May 30, 2024, Inhibrx, Inc.,
a Delaware corporation (the “Company”), completed the transactions contemplated by the Agreement and Plan of Merger, dated
as of January 22, 2024 (the “Merger Agreement”), by and among Aventis Inc., a Pennsylvania corporation (“Parent”)
and wholly owned subsidiary of Sanofi (“Sanofi”), Art Acquisition Sub, Inc. (“Merger Sub”) and the Company.
Pursuant to the Merger Agreement, Merger Sub merged with and into the Company (the “Merger”), with the Company surviving the
Merger as a wholly owned subsidiary of Parent.
In connection with and as a condition to the Merger,
on May 29, 2024, the Company completed the previously announced transactions pursuant to the Separation and Distribution Agreement,
dated as of January 22, 2024 (the “Separation and Distribution Agreement”), by and among the Company, Inhibrx Biosciences, Inc.
(“SpinCo”) and, with respect to certain sections, Parent, pursuant to which, prior to the effective time of the Merger (the
“Effective Time”): (i) the Company effected a pre-closing reorganization (the “Pre-Closing Reorganization”),
which generally resulted in (x) the Company owning, assuming or retaining all assets and liabilities primarily related to INBRX-101,
an optimized, recombinant alpha-1 antitrypsin (“AAT”) augmentation therapy currently in a registrational trial for the treatment
of patients with alpha-1 antitrypsin deficiency (“AATD”), and (y) SpinCo owning, assuming or retaining all other assets
and liabilities of the Company and its subsidiaries, including those relating to the Company’s platform for the research, development,
manufacture and commercialization of INBRX-105, INBRX-106 and INBRX-109; and (ii) thereafter, the Company distributed to its
stockholders of record as of the close of business on May 17, 2024 (the “distribution record date”) 92% of the issued
and outstanding shares of common stock of SpinCo, par value $0.0001 per share (“SpinCo Common Stock”), on a pro rata basis
(the “Spin-Off”), at a ratio of one (1) share of SpinCo common stock for every four (4) shares of the Company’s
issued and outstanding common stock, par value $0.0001 per share (the “Company common stock”), held on the distribution record
date. SpinCo is continuing as a separate public company and the Company retained 8% of the issued and outstanding shares of SpinCo common
stock as of the effective time of the Spin-Off.
A copy of the Merger Agreement was filed as Exhibit 2.1
and a copy of the Separation and Distribution Agreement was filed as Exhibit 2.2 to the Current Report on Form 8-K filed by
the Company with the Securities and Exchange Commission (the “SEC”) on January 23, 2024, and are incorporated herein
by reference. The foregoing descriptions of the Merger Agreement and Separation and Distribution Agreement do not purport to be complete
and are qualified in their entirety by reference to the full text of the Merger Agreement and the Separation and Distribution Agreement.
Item 1.02 Termination of a Material Definitive Agreement.
The information set forth in the Introductory Note
of this Current Report on Form 8-K is incorporated in this Item 1.02 by reference.
On May 30, 2024 (the “Payoff Date”),
the loan and security agreement, dated as of July 15, 2020 (as amended, restated, supplemented or otherwise modified from time to
time, the “2020 Loan Agreement”), by and among the Company and Oxford Finance LLC (“Oxford”), was terminated.
On the Payoff Date, an affiliate of Sanofi, on behalf of the Company, repaid in full all of the indebtedness and other obligations and
liabilities owed by the Company to the lenders thereunder in an amount equal to approximately $223.2 million, which included prepayment
penalties. In connection with the termination and repayment in full of the indebtedness and other obligations and liabilities under the
2020 Loan Agreement, all related security interests granted by or arising under the 2020 Loan Agreement were automatically released and
discharged.
A copy of the 2020 Loan Agreement was filed as
Exhibit 10.21 to the Annual Report on Form 10-K filed by the Company with the SEC on February 28, 2024, and is incorporated
herein by reference. The foregoing description of the 2020 Loan Agreement does not purport to be complete and is qualified in its entirety
by reference to the full text of the 2020 Loan Agreement.
Item 2.01 Completion of Acquisition or Disposition of Assets.
The information set forth in the Introductory Note
of this Current Report on Form 8-K is incorporated in this Item 2.01 by reference.
At the Effective Time, each share of Company common
stock that was issued and outstanding immediately prior to the Effective Time (other than (A) Company common stock owned by the Company
as treasury shares, (B) Company common stock owned by Parent or Merger Sub and (C) any dissenting shares) was automatically
cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the
“Closing Amount”), plus (ii) one (1) contractual contingent value right (“CVR”) representing the right
to receive a contingent payment of $5.00, without interest thereon, in cash (the “Milestone Payment”) upon the achievement
of a regulatory milestone (the “Milestone”) set forth in the CVR Agreement (as defined below) ((i) and (ii) collectively,
the “Merger Consideration”).
At the Effective Time, each option to purchase
shares of Company common stock (each, a “Company Option”) granted by the Company under the Company’s Amended and Restated
2017 Equity Incentive Plan that was outstanding as of immediately prior to the Effective Time (after giving effect to the Spin-Off and
the provisions of the Separation and Distribution Agreement), whether or not then vested:
| (i) | having an exercise price per share of Company common stock that was less than the Closing Amount was cancelled and immediately ceased
to be outstanding, and was converted into the right to receive (a) an amount in cash, without interest, equal to the product of (x) the
total number of shares of Company common stock subject to such Company Option immediately prior to the Effective Time, multiplied by
(y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of Company common stock under such
Company Option (such amount, the “Closing Option Payment”), and (b) one (1) CVR for each share of Company common
stock subject to such Company Option; |
| (ii) | having an exercise price per share that was equal to or
greater than the Closing Amount and less than the Merger Consideration (each such Company
Option, a “Closing Date Underwater Option”) was cancelled. If the Milestone is achieved, the cash amount to be paid
in respect of such Closing Date Underwater Option will be equal to (x) the sum of the Closing Amount plus the Milestone Payment (i.e.,
$35.00) minus (y) the per share exercise price of such Closing Date Underwater Option;
and |
| (iii) | having an exercise price per share that was equal to or
greater than the Merger Consideration was cancelled without any consideration being payable
in respect thereof, and has no further force or effect. |
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
In
connection with the consummation of the Merger, the Company requested that The Nasdaq Global Market suspend trading of the Company
common stock as of May 30, 2024, and file with the SEC a Notification of Removal from Listing and/or Registration on Form 25
to delist and deregister the shares of the Company common stock under Section 12(b) of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”). The Company intends to file with the SEC a certification on Form 15 requesting that
the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act be suspended.
Item 3.03 Material Modification to Rights of Security Holders.
The information set forth in the Introductory Note, Item
2.01, Item 3.01 and Item 5.01 of this Current Report on Form 8-K is incorporated in this Item 3.03 by reference.
In connection with the completion of the Merger,
at the Effective Time, holders of shares of Company common stock and Company Options ceased to have any rights in connection with their
holding of such securities (other than their right to receive the Merger Consideration, or the applicable amount thereof, as described
in Item 2.01 above) and accordingly, no longer have any interest in the Company’s future earnings or growth.
Item 5.01 Changes in Control of Registrant.
The information set forth in the Introductory Note
of this Current Report on Form 8-K is incorporated in this Item 5.01 by reference.
As a result of the consummation of the Merger,
a change of control of the Company occurred, and the Company became a wholly owned subsidiary of Parent. The aggregate Merger Consideration
was approximately $2 billion. Parent financed the Merger with existing cash on hand.
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In accordance with the Merger Agreement, at the
Effective Time, each of Mark P. Lappe, Douglas G. Forsyth, Jon Faiz Kayyem, Kimberly Manhard and Kristiina Vuori resigned from the board
of directors of the Company. As of the Effective Time, in accordance with the Merger Agreement, Michael J. Tolpa, the sole director of
Merger Sub immediately prior to the Effective Time, became the sole director of the Company as the surviving corporation.
At the Effective Time, each of Mark P. Lappe, Kelly
D. Deck and Brendan P. Eckelman resigned as officers of the Company. As of the Effective Time, in accordance with the Merger Agreement,
Michael J. Tolpa, the President and sole officer of Merger Sub immediately prior to the Effective Time became the President and sole officer
of the Company as the surviving corporation. After the Effective Time, Michael J. Tolpa, as the sole director of the Company, passed resolutions
appointing (or confirming the continued appointment of) the following individuals as officers of the Company: (i) Dietmar Berger,
President, (ii) Stephen Smith, Vice President, (iii) Stephen Kalinchak, Assistant Secretary and (iv) Michael J. Tolpa,
Treasurer.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.
The information set forth in the Introductory Note
of this Current Report on Form 8-K is incorporated in this Item 5.03 by reference.
At the Effective Time, the amended and restated
certificate of incorporation of the Company that was in effect immediately prior to the Effective Time was amended and restated to be
in the form of Annex II to the Merger Agreement (the “Second Amended and Restated Certificate”). In addition, at the Effective
Time, the amended and restated bylaws of the Company as in effect immediately prior to the Effective Time were amended and restated in
their entirety (the “Second Amended and Restated Bylaws).
The foregoing
descriptions of the Second Amended and Restated Certificate and Second Amended and Restated Bylaws are qualified in their entirety by
reference to the full text of the Second Amended and Restated Certificate and Second Amended and Restated Bylaws, copies of which are
filed as Exhibit 3.1 and Exhibit 3.2 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.
Item 8.01 Other Events.
Contingent Value Rights Agreement
At
the Effective Time, pursuant to the Merger Agreement, Parent entered into a Contingent Value Rights Agreement between Parent and Continental
Stock Transfer & Trust Company (the “Rights Agent”), in substantially the form attached to the Merger Agreement (the
“CVR Agreement”). Each CVR represents the right to receive a contingent payment of $5.00 in cash (or less in the case of Closing
Date Underwater Options), without interest, payable to the Rights Agent for the benefit of the holders of CVRs, if the following milestone
is achieved:
| ● | The final approval by the U.S. Food and Drug Administration (“FDA”), on or prior to June 30,
2027, of the new drug application or supplemental new drug application filed with the FDA pursuant to Section 351 of the Public Health
Service Act and 21 CFR §§ 600 et seq. (for clarity, including accelerated approval) that is necessary for the commercial marketing
and sale of the Company’s precisely engineered recombinant human AAT-Fc fusion protein, also known as INBRX-101, in the United States
of America for the treatment of patients with AATD and clinical evidence of emphysema following the clinical trial with identifier INBRX101-01-201,
titled “A Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity,
and Safety of INBRX-101 Compared to Plasma Derived Alpha-1 Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults with Alpha-1 Antitrypsin
Deficiency Emphysema,” regardless of any obligation to conduct any post-marketing or confirmatory study. |
The
right to the contingent consideration as evidenced by the CVR Agreement is a contractual right only and is not transferable, except in
the limited circumstances specified in the CVR Agreement.
The
foregoing description of the CVR Agreement and the transactions contemplated thereby does not purport to be complete, and is subject to,
and qualified in its entirety by reference to, the full text of the CVR Agreement, which is designated as Annex III within the Merger
Agreement, which is attached as Exhibit 2.1 to the Current Report on Form 8-K, filed with the SEC on January 22, 2024 and
is incorporated herein by reference. It is not intended to provide any factual information about the Company, Parent or their respective
subsidiaries and affiliates. The representations, warranties and covenants contained in the CVR Agreement have been made solely for the
purposes of the CVR Agreement and as of specified dates; were made solely for the benefit of the parties to the CVR Agreement; are not
intended as statements of fact to be relied upon by the Company’s stockholders, but rather as a way of allocating the risk between
the parties in the event that statements therein prove to be inaccurate; have been modified or qualified by certain confidential disclosures
that were made between the parties in connection with the negotiation of the CVR Agreement, which disclosures are not reflected in the
CVR Agreement itself; may have been made for the purposes of allocating contractual risk between the parties to the CVR Agreement instead
of establishing these matters as facts; may no longer be true as of a given date; and may apply standards of materiality in a way that
is different from what may be viewed as material by the Company stockholders. The Company’s stockholders should not rely on the
representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or conditions
of the Company, Parent or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the
representations, warranties and covenants may change after the date of the CVR Agreement, which subsequent information may or may not
be fully reflected in the Company’s or Parent’s public disclosures.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
|
Exhibit Description |
2.1 |
|
Agreement and Plan of Merger, dated as of January 22, 2024, by and among Inhibrx, Inc., Aventis, Inc. and Art Acquisition Sub, Inc. (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed on January 23, 2024, and incorporated herein by reference). |
2.2 |
|
Separation and Distribution Agreement, dated January 22, 2024, by and among Inhibrx, Inc. and Aventis Inc. (filed as Exhibit 2.2 to the Company’s Current Report on Form 8-K, filed on January 23, 2024, and incorporated herein by reference). |
3.1 |
|
Second Amended and Restated Certificate of Incorporation of Inhibrx, Inc. |
3.2 |
|
Second Amended and Restated Bylaws of Inhibrx, Inc. |
104 |
|
The cover page of this Current Report on Form 8-K formatted as Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 30, 2024
|
Inhibrx, Inc. |
|
|
|
By: |
/s/ Michael J. Tolpa |
|
|
Name: Michael J. Tolpa |
|
|
Title: President |
Exhibit 3.1
SIXTH AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF
INHIBRX, INC.
FIRST: The name of the corporation is: Inhibrx, Inc.
SECOND: The address of the
registered office of the Corporation in the State of Delaware is: 251 Little Falls Drive, in the City of Wilmington, County of New Castle,
19808. The name of its registered agent for service of process in the State of Delaware at such address is Corporation Service Company.
THIRD: The purpose of the
Corporation is to engage in any and all lawful acts or activities for which corporations may be organized under the DGCL.
FOURTH: The total number of
shares of capital stock which the Corporation shall have authority to issue is one hundred (100), all of which shares shall be common
stock each having a par value of $0.0001 per share.
FIFTH: In addition to the
powers and authority herein before or by statute expressly conferred upon them, the board of directors of the Corporation (the “Board
of Directors”) is hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by
the Corporation, subject to the provisions of the DGCL, this Sixth Amended and Restated Certificate of Incorporation and the bylaws of
the Corporation.
SIXTH: In furtherance and
not in limitation of the powers conferred by law, subject to any limitations contained in this Sixth Amended and Restated Certificate
of Incorporation, the bylaws of the Corporation may be adopted, amended or repealed by a majority of the Board of Directors, but any bylaws
adopted by the Board of Directors may be amended or repealed by the stockholders entitled to vote thereon. Election of directors need
not be by written ballot unless the bylaws of the Corporation so provide.
SEVENTH: The Corporation shall provide indemnification as
follows:
1. Actions,
Suits and Proceedings Other than by or in the Right of the Corporation. The Corporation shall indemnify each person who was or is
a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he or she is
or was, or has agreed to become, a director or officer of the Corporation, or is or was serving, or has agreed to serve, at the request
of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership,
joint venture, trust or other enterprise (including any employee benefit plan) (all such persons being referred to hereafter as an “Indemnitee”),
or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees),
liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act
of 1974), and amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with such action,
suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed to
be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable
cause to believe his or her conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction
or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in
good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and,
with respect to any criminal action or proceeding, had reasonable cause to believe that his or her conduct was unlawful.
2. Actions
or Suits by or in the Right of the Corporation. The Corporation shall indemnify any Indemnitee who was or is a party to or threatened
to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment
in its favor by reason of the fact that Indemnitee is or was, or has agreed to become, a director or officer of the Corporation, or is
or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or
in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit
plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’
fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in
connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee
reasonably believed to be in, or not opposed to, the best interests of the Corporation, except that no indemnification shall be made under
this Section 2 of this Article SEVENTH in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged
to be liable to the Corporation, unless, and only to the extent, that the Court of Chancery of Delaware or the court in which such action
or suit was brought shall determine upon application that, despite the adjudication of such liability but in view of all the circumstances
of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses (including attorneys’ fees) which
the Court of Chancery of Delaware or such other court shall deem proper.
3. Indemnification
for Expenses of Successful Party. Notwithstanding any other provisions of this Article SEVENTH, to the extent that an Indemnitee
has been successful, on the merits or otherwise, in defense of any action, suit or proceeding referred to in Sections 1 and 2 of this
Article SEVENTH, or in defense of any claim, issue or matter therein, or on appeal from any such action, suit or proceeding, Indemnitee
shall be indemnified against all expenses (including attorneys’ fees) actually and reasonably incurred by or on behalf of Indemnitee
in connection therewith. Without limiting the foregoing, if any action, suit or proceeding is disposed of, on the merits or otherwise
(including a disposition without prejudice), without (i) the disposition being adverse to Indemnitee, (ii) an adjudication that
Indemnitee was liable to the Corporation, (iii) a plea of guilty or nolo contendere by Indemnitee, (iv) an adjudication
that Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests
of the Corporation, and (v) with respect to any criminal proceeding, an adjudication that Indemnitee had reasonable cause to believe
his or her conduct was unlawful, Indemnitee shall be considered for the purposes hereof to have been wholly successful with respect
thereto.
4. Notification
and Defense of Claim. As a condition precedent to an Indemnitee’s right to be indemnified, such Indemnitee must notify the Corporation
in writing as soon as practicable of any action, suit, proceeding or investigation involving such Indemnitee for which indemnity will
or could be sought unless the Corporation has confirmed to the Indemnitee that it is aware of such action, suit, proceeding or investigation
and that indemnity will or could be sought. With respect to any action, suit, proceeding or investigation of which the Corporation is
so notified, the Corporation will be entitled to participate therein at its own expense and/or to assume the defense thereof at its own
expense, with legal counsel reasonably acceptable to Indemnitee. After notice from the Corporation to Indemnitee of its election so to
assume such defense, the Corporation shall not be liable to Indemnitee for any legal or other expenses subsequently incurred by Indemnitee
in connection with such action, suit, proceeding or investigation, other than as provided below in this Section 4 of this Article SEVENTH.
Indemnitee shall have the right to employ his or her own counsel in connection with such action, suit, proceeding or investigation, but
the fees and expenses of such counsel incurred after notice from the Corporation of its assumption of the defense thereof shall be at
the expense of Indemnitee unless (i) the employment of counsel by Indemnitee has been authorized by the Corporation, (ii) counsel
to Indemnitee shall have reasonably concluded that there may be a conflict of interest or position on any significant issue between the
Corporation and Indemnitee in the conduct of the defense of such action, suit, proceeding or investigation or (iii) the Corporation
shall not in fact have employed counsel to assume the defense of such action, suit, proceeding or investigation, in each of which cases
the fees and expenses of counsel for Indemnitee shall be at the expense of the Corporation, except as otherwise expressly provided by
this Article SEVENTH. The Corporation shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim
brought by or in the right of the Corporation or as to which counsel for Indemnitee shall have reasonably made the conclusion provided
for in clause (ii) above. The Corporation shall not be required to indemnify Indemnitee under this Article SEVENTH for any amounts
paid in settlement of any action, suit, proceeding or investigation effected without its written consent. The Corporation shall not settle
any action, suit, proceeding or investigation in any manner which would impose any penalty or limitation on Indemnitee without Indemnitee’s
written consent. Neither the Corporation nor Indemnitee will unreasonably withhold or delay its consent to any proposed settlement.
5. Advance
of Expenses. Subject to the provisions of Section 6 of this Article SEVENTH, in the event of any threatened or pending action,
suit, proceeding or investigation of which the Corporation receives notice under this Article SEVENTH, any expenses (including attorneys’
fees) incurred by or on behalf of Indemnitee in defending an action, suit, proceeding or investigation or any appeal therefrom shall be
paid by the Corporation in advance of the final disposition of such matter; provided, however, that the payment of such expenses incurred
by or on behalf of Indemnitee in advance of the final disposition of such matter shall be made only upon receipt of an undertaking by
or on behalf of Indemnitee to repay all amounts so advanced in the event that it shall ultimately be determined by final judicial decision
from which there is no further right to appeal that Indemnitee is not entitled to be indemnified by the Corporation as authorized in this
Article SEVENTH; and provided further that no such advancement of expenses shall be made under this Article SEVENTH if it is
determined (in the manner described in Section 6 of this Article SEVENTH) that (i) Indemnitee did not act in good faith
and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the Corporation, or (ii) with respect
to any criminal action or proceeding, Indemnitee had reasonable cause to believe his or her conduct was unlawful. Such undertaking
shall be accepted without reference to the financial ability of Indemnitee to make such repayment.
6. Procedure
for Indemnification and Advancement of Expenses. In order to obtain indemnification or advancement of expenses pursuant to Section 1,
2, 3 or 5 of this Article SEVENTH, an Indemnitee shall submit to the Corporation a written request. Any such advancement of expenses
shall be made promptly, and in any event within 60 days after receipt by the Corporation of the written request of Indemnitee, unless
(i) the Corporation has assumed the defense pursuant to Section 4 of this Article SEVENTH (and none of the circumstances
described in Section 4 of this Article SEVENTH that would nonetheless entitle the Indemnitee to indemnification for the fees
and expenses of separate counsel have occurred) or (ii) the Corporation determines within such 60-day period that Indemnitee did
not meet the applicable standard of conduct set forth in Section 1, 2 or 5 of this Article SEVENTH, as the case may be. Any
such indemnification, unless ordered by a court, shall be made with respect to requests under Section 1 or 2 of this Article SEVENTH
only as authorized in the specific case upon a determination by the Corporation that the indemnification of Indemnitee is proper because
Indemnitee has met the applicable standard of conduct set forth in Section 1 or 2 of this Article SEVENTH, as the case may be.
Such determination shall be made in each instance (a) by a majority vote of the directors of the Corporation consisting of persons
who are not at that time parties to the action, suit or proceeding in question (“disinterested directors”), whether or not
a quorum, (b) by a committee of disinterested directors designated by majority vote of disinterested directors, whether or not a
quorum, (c) if there are no disinterested directors, or if the disinterested directors so direct, by independent legal counsel (who
may, to the extent permitted by law, be regular legal counsel to the Corporation) in a written opinion, or (d) by the stockholders
of the Corporation.
7. Remedies.
The right to indemnification or advancement of expenses as granted by this Article SEVENTH shall be enforceable by Indemnitee in
any court of competent jurisdiction. Neither the failure of the Corporation to have made a determination prior to the commencement of
such action that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an
actual determination by the Corporation pursuant to Section 6 of this Article SEVENTH that Indemnitee has not met such applicable
standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.
In any suit brought by Indemnitee to enforce a right to indemnification, or brought by the Corporation to recover an advancement of expenses
pursuant to the terms of an undertaking, the Corporation shall have the burden of proving that Indemnitee is not entitled to be indemnified,
or to such advancement of expenses, under this Article SEVENTH. Indemnitee’s expenses (including attorneys’ fees) reasonably
incurred in connection with successfully establishing Indemnitee’s right to indemnification, in whole or in part, in any such proceeding
shall also be indemnified by the Corporation. Notwithstanding the foregoing, in any suit brought by Indemnitee to enforce a right to indemnification
hereunder it shall be a defense that the Indemnitee has not met any applicable standard for indemnification set forth in the DGCL.
8. Limitations.
Notwithstanding anything to the contrary in this Article SEVENTH, except as set forth in Section 7 of this Article SEVENTH,
the Corporation shall not indemnify an Indemnitee pursuant to this Article SEVENTH in connection with a proceeding (or part thereof)
initiated by such Indemnitee unless the initiation thereof was approved by the Board of Directors of the Corporation. Notwithstanding
anything to the contrary in this Article SEVENTH, the Corporation shall not indemnify an Indemnitee to the extent such Indemnitee
is reimbursed from the proceeds of insurance, and in the event the Corporation makes any indemnification payments to an Indemnitee and
such Indemnitee is subsequently reimbursed from the proceeds of insurance, such Indemnitee shall promptly refund indemnification payments
to the Corporation to the extent of such insurance reimbursement.
9. Subsequent
Amendment. No amendment, termination or repeal of this Article SEVENTH or of the relevant provisions of the General Corporation
Law of the State of Delaware or any other applicable laws shall adversely affect or diminish in any way the rights of any Indemnitee to
indemnification under the provisions hereof with respect to any action, suit, proceeding or investigation arising out of or relating to
any actions, transactions or facts occurring prior to the final adoption of such amendment, termination or repeal.
10. Other
Rights. The indemnification and advancement of expenses provided by this Article SEVENTH shall not be deemed exclusive of any
other rights to which an Indemnitee seeking indemnification or advancement of expenses may be entitled under any law (common or statutory),
agreement or vote of stockholders or disinterested directors or otherwise, both as to action in Indemnitee’s official capacity and
as to action in any other capacity while holding office for the Corporation, and shall continue as to an Indemnitee who has ceased to
be a director or officer, and shall inure to the benefit of the estate, heirs, executors and administrators of Indemnitee. Nothing contained
in this Article SEVENTH shall be deemed to prohibit, and the Corporation is specifically authorized to enter into, agreements with
officers and directors providing indemnification rights and procedures different from those set forth in this Article SEVENTH. In
addition, the Corporation may, to the extent authorized from time to time by its Board of Directors, grant indemnification rights to other
employees or agents of the Corporation or other persons serving the Corporation and such rights may be equivalent to, or greater or less
than, those set forth in this Article SEVENTH.
11. Partial
Indemnification. If an Indemnitee is entitled under any provision of this Article SEVENTH to indemnification by the Corporation
for some or a portion of the expenses (including attorneys’ fees), liabilities, losses, judgments, fines (including excise taxes
and penalties arising under the Employee Retirement Income Security Act of 1974) or amounts paid in settlement actually and reasonably
incurred by or on behalf of Indemnitee in connection with any action, suit, proceeding or investigation and any appeal therefrom but not,
however, for the total amount thereof, the Corporation shall nevertheless indemnify Indemnitee for the portion of such expenses (including
attorneys’ fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement
Income Security Act of 1974) or amounts paid in settlement to which Indemnitee is entitled.
12. Insurance.
The Corporation may purchase and maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of
the Corporation or another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan) against
any expense, liability or loss incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not
the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL.
13. Savings
Clause. If this Article SEVENTH or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction,
then the Corporation shall nevertheless indemnify each Indemnitee as to any expenses (including attorneys’ fees), liabilities, losses,
judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) and amounts
paid in settlement in connection with any action, suit, proceeding or investigation, whether civil, criminal or administrative, including
an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article SEVENTH
that shall not have been invalidated and to the fullest extent permitted by applicable law.
14. Terms
used herein and defined in Section 145(h) and Section 145(i) of the DGCL shall have the respective meanings assigned
to such terms in such Section 145(h) and Section 145(i).
EIGHTH: Meetings of stockholders
may be held within or without the State of Delaware, as the bylaws may provide. The books of the Corporation may be kept (subject to any
provision contained in the DGCL) outside the State of Delaware at such place or places as may be designated from time to time by the Board
of Directors or in the bylaws of the Corporation.
NINTH: The Board of Directors
reserves the right to amend, alter, change or repeal any provision contained in this Sixth Amended and Restated Certificate of Incorporation,
in the manner now or hereafter prescribed by statute, and all rights conferred upon stockholders herein are granted subject to this reservation.
Exhibit 3.2
SECOND AMENDED AND RESTATED BYLAWS
OF
INHIBRX, INC.
(a Delaware corporation)
Article I
Stockholders
Section 1. Annual
Meetings. The annual meeting of the stockholders of Inhibrx, Inc. (the “Corporation”) for the election of
directors and for the transaction of such other business as may properly come before the meeting shall be held each year at such date
and time, within or without the State of Delaware, as the board of directors of the Corporation (the “Board of Directors”)
shall determine.
Section 2. Special
Meetings. Special meetings of stockholders for the transaction of such business as may properly come before the meeting or for any
other purpose or purposes may be called by order of the Board of Directors or by stockholders holding together at least a majority of
all the shares of the Corporation entitled to vote at the meeting, and shall be held at such date and time, within or without the State
of Delaware, as may be specified by such order. Whenever the directors shall fail to fix such place, the meeting shall be held at the
principal executive office of the Corporation.
Section 3. Notice
of Meetings. Written notice of all meetings of the stockholders, stating the place (if any), date and hour of the meeting, the means
of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting,
and the place within the city or other municipality or community at which the list of stockholders may be examined, shall be mailed or
delivered (physically or electronically) to each stockholder entitled to notice of or to vote at such meeting not less than 10 nor more
than 60 days prior to the meeting. Notice of any special meeting shall state in general terms the purpose or purposes for which the meeting
is to be held, and at such special meeting, only such business shall be conducted as shall be specified in the notice of meeting. Stockholders
may participate in any such meeting by means of a conference telephone or similar communications equipment by means of which all persons
participating in the meeting can hear each other, and such participation in meeting shall constitute presence at such meeting. Without
limiting the manner by which notice otherwise may be given effectively to stockholders, notice of meetings may be given to stockholders
by means of electronic transmission in accordance with applicable law. Notice of any meeting need not be given to any stockholder who
shall, either before or after the meeting, submit a waiver of notice or who shall attend such meeting, except when the stockholder attends
for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully
called or convened. Any stockholder so waiving notice of the meeting shall be bound by the proceedings of the meeting in all respects
as if due notice thereof had been given.
Section 4. Stockholder
Lists. The officer who has charge of the stock ledger of the Corporation shall prepare and make, at least 10 days before every meeting
of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the
address of each stockholder and the number and class of shares registered in the name of each stockholder. Such list shall be open to
the examination of any stockholder, for any purpose germane to the meeting, either at a place within the city where the meeting is to
be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be
held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected
by any stockholder who is present.
The stock ledger shall be the
only evidence as to who are the stockholders entitled to examine the stock ledger, the list required by this section or the books of the
Corporation, or to vote in person or by proxy at any meeting of stockholders.
Section 5. Quorum.
Except as otherwise provided by law or the Corporation’s Certificate of Incorporation, a quorum for the transaction of business
at any meeting of stockholders shall consist of the holders of record of a majority of the issued and outstanding shares of the capital
stock of the Corporation entitled to vote at the meeting, present in person or by proxy. At all meetings of the stockholders at which
a quorum is present, all matters, except as otherwise provided by law or the Certificate of Incorporation, shall be decided by the vote
of the holders of a majority of the shares entitled to vote thereat present in person or by proxy. If there be no such quorum, the holders
of a majority of such shares so present or represented may adjourn the meeting from time to time, without further notice, until a quorum
shall have been obtained. When a quorum is once present it is not broken by the subsequent withdrawal of any stockholder.
Section 6. Organization.
Meetings of stockholders shall be presided over by the Chairman, if any, or if none or in the Chairman’s absence the Vice-Chairman,
if any, or if none or in the Vice-Chairman’s absence, the President, if any, or if none or in the President’s absence a Vice-President,
or, if none of the foregoing is present, by a chairman to be chosen by the stockholders entitled to vote who are present in person or
by proxy at the meeting. The Secretary of the Corporation, or in the Secretary’s absence, the presiding officer of the meeting shall
appoint any person present to act as secretary of the meeting.
Section 7. Voting;
Proxies; Required Vote.
(a) At
each meeting of stockholders, every stockholder entitled to vote at such meeting shall be entitled to vote in person or by proxy appointed
by instrument in writing, subscribed by such stockholder or by such stockholder’s duly authorized attorney-in-fact (but no such
proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period), and, unless the Certificate
of Incorporation provides otherwise, shall have one vote for each share of stock entitled to vote registered in the name of such stockholder
on the books of the Corporation on the applicable record date fixed pursuant to these Bylaws. At all elections of directors the voting
may but need not be by ballot and a plurality of the votes cast there shall elect such directors. Except as otherwise required by law
or the Certificate of Incorporation, any other action shall be authorized by the vote of the majority of the shares present in person
or by proxy at the meeting and entitled to vote on the subject matter.
(b) Any
action required or permitted to be taken at any meeting of stockholders may, except as otherwise required by law or the Certificate of
Incorporation, be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action
so taken, shall be signed by the holders of record of the issued and outstanding capital stock of the Corporation having not less than
the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote
thereon were present and voted, and the writing or writings are filed with the permanent records of the Corporation. Prompt notice of
the taking of corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have
not consented in writing.
Section 8. Inspectors.
The Board of Directors, in advance of any meeting, may, but need not, appoint one or more inspectors of election to act at the meeting
or any adjournment thereof. If an inspector or inspectors are not so appointed, the person presiding at the meeting may, but need not,
appoint one or more inspectors. In case any person who may be appointed as an inspector fails to appear or act, the vacancy may be filled
by an appointment made by the directors in advance of the meeting or at the meeting by the person presiding thereat. Each inspector, if
any, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector
at such meeting with strict impartiality and according to the best of his or her ability. The inspectors, if any, shall determine the
number of shares of stock outstanding and the voting power of each, the shares of stock represented at the meeting, the existence of a
quorum, and the validity and effect of proxies, and shall receive votes, ballots or consents, hear and determine all challenges and questions
arising in connection with the right to vote, count and tabulate all votes, ballots or consents, determine the result, and do such acts
as are proper to conduct the election or vote with fairness to all stockholders. On request of the person presiding at the meeting, the
inspector or inspectors, if any, shall make a report in writing of any challenge, question or matter determined by such inspector or inspectors
and execute a certificate of any fact found by such inspector or inspectors.
Section 9. Written
Consent of Stockholders Without a Meeting. Any action to be taken at any annual or special meeting of stockholders may be taken without
a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action to be so taken, shall
be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or
take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered (physically or
electronically) to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business, or
an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Prompt
notice of the taking of the corporate action without a meeting by less than unanimous written consent shall, to the extent required by
applicable law, be given to those stockholders who have not consented in writing, and who, if the action had been taken at a meeting,
would have been entitled to notice of the meeting if the record date for notice of such meeting had been the date that written consents
signed by a sufficient number of holders to take the action were delivered to the Corporation.
Section 10. Remote
Communication. Stockholders and proxy holders not physically present at a meeting of stockholders may, by means of remote communication:
(i) participate in a meeting of stockholders; and (ii) be deemed present in person and vote at a meeting of stockholders, whether
such meeting is to be held at a designated place or solely by means of remote communication, provided that (A) the Corporation shall
implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication
is a stockholder or proxyholder, (B) the Corporation shall implement reasonable measures to provide such stockholders and proxy holders
a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders, including an opportunity
to read or hear the proceedings of the meeting substantially concurrently with such proceedings, and (C) if any stockholder or proxy
holder votes or takes other action at the meeting by means of remote communication, a record of such votes or other action shall be maintained
by the Corporation.
Article II
Board of Directors
Section 1. General
Powers. The business, property and affairs of the Corporation shall be managed by, or under the direction of, the Board of Directors.
Section 2. Qualification;
Number; Term; Compensation.
(a) Each
director shall be at least 18 years of age. A director need not be a stockholder, a citizen of the United States or a resident of the
State of Delaware. The number of directors constituting the entire Board of Directors shall be fixed initially by the incorporator and
thereafter by the Board of Directors and shall be at least one, or such larger number as may be fixed initially by the incorporator and
thereafter from time to time by the Board of Directors, one of whom may be selected by the Board of Directors to be its Chairman. The
use of the phrase “entire Board of Directors” herein refers to the total number of directors which the Corporation would have
if there were no vacancies.
(b) Directors
who are elected at an annual meeting of stockholders, and directors who are elected in the interim to fill vacancies and newly created
directorships, shall hold office until the next annual meeting of stockholders and until their successors are elected and qualified or
until their earlier resignation or removal.
(c) Unless
otherwise restricted by the Certificate of Incorporation or these Bylaws, the Board of Directors shall have the authority to fix the compensation
of directors. The directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors and may be paid
a fixed sum for attendance at each meeting of the Board of Directors or a stated salary as director. No such payment shall preclude any
director from serving the Corporation in any other capacity and receiving compensation therefor. Members of special or standing committees
may be allowed like compensation for attending committee meetings.
Section 3. Quorum
and Manner of Voting. Except as otherwise provided by law, a majority of the entire Board of Directors shall constitute a quorum.
A majority of the directors present, whether or not a quorum is present, may adjourn a meeting from time to time to another time and place
without notice. The vote of the majority of the directors present at a meeting at which a quorum is present shall be the act of the Board
of Directors. Each director shall be entitled to one vote on exactly the matter presented to the Board of Directors for approval.
Section 4. Places
of Meetings. Meetings of the Board of Directors may be held at any place within or without the State of Delaware, as may from time
to time be fixed by resolution of the Board of Directors, or as may be specified in the notice of meeting, if any.
Section 5. Annual
Meeting. Following the annual meeting of stockholders, the newly elected Board of Directors shall meet for the purpose of the election
of officers and the transaction of such other business as may properly come before the meeting. Such meeting may be held without notice
immediately after the annual meeting of stockholders at the same place at which such stockholders’ meeting is held.
Section 6. Regular
Meetings. Regular meetings of the Board of Directors shall be held at such times and places as the Board of Directors shall from time
to time determine by resolution. Notice need not be given of regular meetings of the Board of Directors held at times and places fixed
by resolution of the Board of Directors and promptly communicated to all directors then in office.
Section 7. Special
Meetings. Special meetings of the Board of Directors shall be held whenever called by the Chairman, the President or by a majority
of the directors then in office.
Section 8. Notice
of Meetings. Whenever required, notice of the place, date and time and the purpose or purposes of each meeting of the Board of Directors
shall be given to each director not less than two calendar days before the day of the meeting by mail, telephone, facsimile, e-mail, or
by personal delivery.
Section 9. Meetings
by Means of Conference Telephone. Unless otherwise provided by the Certificate of Incorporation or these Bylaws, members of the Board
of Directors, or any committee designated by the Board of Directors, may participate in a meeting of the Board of Directors or such committee
by means of a conference telephone or similar communication equipment by means of which all persons participating in the meeting can hear
each other, and such participation in a meeting pursuant to this Section 8 shall constitute presence at such meeting.
Section 10. Organization.
The Chairman, if there be one, or if none or in the Chairman’s absence or inability to act the Vice Chairman, if any, or if none
or in the Vice-Chairman’s absence or inability to act the President, or in the President’s absence or inability to act any
Vice-President who is a member of the Board of Directors, or in such Vice-President’s absence or inability to act, a chairman chosen
by the directors, shall preside at all meetings of the Board of Directors and shall have such other powers and duties as may from time
to time be assigned by the Board of Directors. The Secretary of the Corporation shall act as secretary at all meetings of the Board of
Directors when present, and, in the Secretary’s absence, the presiding officer may appoint any person to act as secretary.
Section 11. Resignation;
Removal. Any director may resign at any time upon written notice to the Corporation and such resignation shall take effect upon receipt
thereof by the President or Secretary, unless otherwise specified in the resignation. Any or all of the directors may be removed, with
or without cause, by the holders of a majority of the shares of stock outstanding and entitled to vote for the election of directors.
Section 12. Vacancies.
Unless otherwise provided in these Bylaws, vacancies on the Board of Directors, whether caused by resignation, death, disqualification,
removal, an increase in the authorized number of directors or otherwise, may be filled by the affirmative vote of a majority of the remaining
directors, although less than a quorum, or by a sole remaining director, or at a special meeting of the stockholders, by the holders
of shares entitled to vote for the election of directors.
Section 13. Action
by Written Consent. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken without a
meeting if all the directors consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the
Board of Directors.
Article III
Committees
Section 1. Appointment.
From time to time the Board of Directors by a resolution adopted by a majority of the entire Board of Directors may appoint any committee
or committees for any purpose or purposes, to the extent lawful, which shall have powers as shall be determined and specified by the Board
of Directors in the resolution of appointment.
Section 2. Procedures,
Quorum and Manner of Acting. Each committee shall fix its own rules of procedure, and shall meet where and as provided by such
rules or by resolution of the Board of Directors. Except as otherwise provided by law, the presence of a majority of the then appointed
members of a committee shall constitute a quorum for the transaction of business by that committee, and in every case where a quorum is
present the affirmative vote of a majority of the members of the committee present shall be the act of the committee. Each committee shall
keep minutes of its proceedings, and actions taken by a committee shall be reported to the Board of Directors.
Section 3. Action
by Written Consent. Any action required or permitted to be taken at any meeting of any committee of the Board of Directors may be
taken without a meeting if all the members of the committee consent thereto in writing, and the writing or writings are filed with the
minutes of proceedings of the committee.
Section 4. Term;
Termination. In the event any person shall cease to be a director of the Corporation, such person shall simultaneously therewith cease
to be a member of any committee appointed by the Board of Directors.
Article IV
Officers
Section 1. Election
and Qualifications. The Board of Directors shall elect the officers of the Corporation, which shall include a President and a Secretary,
and may include, by election or appointment, one or more Vice-Presidents (any one or more of whom may be given an additional designation
of rank or function), a Treasurer and such Assistant Secretaries, such Assistant Treasurers and such other officers as the Board of Directors
may from time to time deem proper. Each officer shall have such powers and duties as may be prescribed by these Bylaws and as may be assigned
by the Board of Directors or the President. Any two or more offices may be held by the same person. The Chairman of the Board of Directors,
if one is appointed, shall, if present, preside at all meetings of the stockholders.
Section 2. Term
of Office and Remuneration. All officers shall hold office until their successors are elected and qualified. Any vacancy in any office
arising from any cause may be filled for the unexpired portion of the term by the Board of Directors. The remuneration of all officers
of the Corporation may be fixed by the Board of Directors or in such manner as the Board of Directors shall provide.
Section 3. Resignation;
Removal. Any officer may resign at any time upon written notice to the Corporation and such resignation shall take effect upon receipt
thereof by the President or Secretary, unless otherwise specified in the resignation. Any officer shall be subject to removal, with or
without cause, at any time by vote of a majority of the entire Board of Directors.
Section 4. President.
The President shall, subject to control of the Board of Directors, have direction and control of the business and officers of the Corporation,
shall have the general powers and duties of management usually vested in the president of a corporation, and shall have such other powers
and duties as may from time to time be assigned by the Board of Directors. The President may appoint and remove assistant officers and
other agents and employees; and may execute and deliver in the name of the Corporation powers of attorney, contracts, bonds and other
obligations and instruments.
Section 5. Vice-President.
A Vice-President may execute and deliver in the name of the Corporation contracts and other obligations and instruments pertaining to
the regular course of the duties of said office, and shall have such other authority as from time to time may be assigned by the Board
of Directors.
Section 6. Treasurer.
The Treasurer (if any) shall in general have all duties incident to the position of Treasurer and such other duties as may be assigned
by the Board of Directors.
Section 7. Secretary.
The Secretary shall in general have all the duties incident to the office of Secretary and such other duties as may be assigned by the
Board of Directors.
Section 8. Other
Officers. Such other officers as the Board of Directors may choose shall perform such duties and have such powers as from time to
time may be assigned to them by the Board of Directors. The Board of Directors may delegate to any other officer of the Corporation the
power to choose such other officers and to prescribe their respective duties and powers.
Article V
Books and Records
Section 1. Location.
The books and records of the Corporation may be kept at such place or places within or outside the State of Delaware as the Board of Directors
or the respective officers in charge thereof may from time to time determine. The record books containing the names and addresses of all
stockholders, the number and class of shares of stock held by each and the dates when they respectively became the owners of record thereof
shall be kept by the Secretary as prescribed in these Bylaws and by such officer or agent as shall be designated by the Board of Directors.
Section 2. Addresses
of Stockholders. Notices of meetings and all other corporate notices may be delivered personally, electronically or mailed to each
stockholder at the stockholder’s address as it appears on the records of the Corporation.
Section 3. Fixing
Date for Determination of Stockholders of Record.
(a) In
order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment
thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the
record date is adopted by the Board of Directors and which record date shall not be more than 60 nor less than 10 days before the date
of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice
of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given,
or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders
of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however,
that the Board of Directors may fix a new record date for the adjourned meeting.
(b) In
order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the Board
of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted
by the Board of Directors and if no record date has been fixed by the Board of Directors, the record date for determining stockholders
entitled to consent to corporate action in writing without a meeting, when no prior action by the Board of Directors is required, shall
be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation
by delivery to its registered office in this State, its principal place of business, or an officer or agent of the Corporation having
custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation’s registered
office shall be by hand or by certified or registered mail, return receipt requested. If no record date has been fixed by the Board of
Directors and prior action by the Board of Directors is required by this article, the record date for determining stockholders entitled
to consent to corporate action in writing without a meeting shall be at the close of business on the day on which the Board of Directors
adopts the resolution taking such prior action.
(c) In
order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment
of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the
purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which
the resolution fixing the record date is adopted and if no record date is fixed, the record date for determining stockholders for any
such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.
Article VI
Certificates Representing Stock
Section 1. Certificates;
Signatures. The shares of the Corporation’s stock may be certificated or uncertificated, as provided under the Delaware General
Corporation Law, as it may be amended and supplemented from time to time (the “DGCL”), and shall be entered in the
books of the Corporation and registered as they are issued. Any certificates representing shares of stock shall be in such form as shall
be approved by the Board of Directors. Every holder of stock represented by certificates and upon request every holder of uncertificated
shares shall be entitled to have a certificate, signed by or in the name of the Corporation by the Chairman or Vice-Chairman of the Board
of Directors, or the President or Vice-President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary
of the Corporation, representing the number of shares registered in certificate form. Any and all signatures on any such certificate may
be facsimiles. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate
shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation
with the same effect as if he were such officer, transfer agent or registrar at the date of issue. The name of the holder of record of
the shares represented thereby, with the number of such shares and the date of issue, shall be entered on the books of the Corporation.
Section 2. Transfers
of Stock. Upon compliance with provisions restricting the transfer or registration of transfer of shares of stock, if any, shares
of capital stock shall be transferable on the books of the Corporation only by the holder of record thereof in person, or by a duly authorized
attorney, upon surrender and cancellation of certificates for a like number of shares, properly endorsed, and the payment of all taxes
due thereon.
Section 3. Fractional
Shares. The Corporation may, but shall not be required to, issue certificates for fractions of a share where necessary to effect authorized
transactions, or the Corporation may pay in cash the fair value of fractions of a share as of the time when those entitled to receive
such fractions are determined, or it may issue scrip in registered or bearer form over the manual or facsimile signature of an officer
of the Corporation or of its agent, exchangeable as therein provided for full shares, but such scrip shall not entitle the holder to any
rights of a stockholder except as therein provided.
Section 4. Rules and
Regulations. The Board of Directors shall have power and authority to make all such rules and regulations as it may deem expedient
concerning the issue, transfer and registration of certificates representing shares of the Corporation.
Section 5. Lost,
Stolen or Destroyed Certificates. The Corporation may issue a new certificate of stock in place of any certificate, theretofore issued
by it, alleged to have been lost, stolen or destroyed, and the Board of Directors may require the owner of any lost, stolen or destroyed
certificate, or his legal representative, to give the Corporation a bond sufficient to indemnify the Corporation against any claim that
may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of any such new certificate.
Article VII
Dividends
Subject always to applicable
law and the Certificate of Incorporation, the Board of Directors shall have full power to determine whether any, and, if any, what part
of any, funds legally available for the payment of dividends shall be declared as dividends and paid to stockholders; the division of
the whole or any part of such funds of the Corporation shall rest wholly within the lawful discretion of the Board of Directors, and it
shall not be required at any time, against such discretion, to divide or pay any part of such funds among or to the stockholders as dividends
or otherwise; and before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends such
sum or sums as the Board of Directors from time to time, in its absolute discretion, deems proper as a reserve or reserves to meet contingencies,
or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for such other purpose as the Board of
Directors shall think conducive to the interest of the Corporation, and the Board of Directors may modify or abolish any such reserve
in the manner in which it was created. Subject to applicable law and the Certificate of Incorporation, dividends upon the shares of capital
stock of the Corporation may be declared by the Board of Directors at any regular or special meeting of the Board of Directors. Dividends
may be paid in cash, in property, or in shares of the Corporation's capital stock, unless otherwise provided by applicable law or the
Certificate of Incorporation.
Article VIII
Ratification
Any transaction, questioned
in any lawsuit on the ground of lack of authority, defective or irregular execution, adverse interest of director, officer or stockholder,
non-disclosure, miscomputation, or the application of improper principles or practices of accounting, may be ratified before or after
judgment, by the Board of Directors or by the stockholders, and if so ratified shall have the same force and effect as if the questioned
transaction had been originally duly authorized. Such ratification shall be binding upon the Corporation and its stockholders and shall
constitute a bar to any claim or execution of any judgment in respect of such questioned transaction.
Article IX
Corporate Seal
The Corporation may have a
corporate seal. The corporate seal shall have inscribed thereon the name of the Corporation and the year of its incorporation, and shall
be in such form and contain such other words and/or figures as the Board of Directors shall determine. The corporate seal may be used
by printing, engraving, lithographing, stamping or otherwise making, placing or affixing, or causing to be printed, engraved, lithographed,
stamped or otherwise made, placed or affixed, upon any paper or document, by any process whatsoever, an impression, facsimile or other
reproduction of said corporate seal.
Article X
Fiscal Year
The fiscal year of the Corporation
shall be fixed, and shall be subject to change, by the Board of Directors. Unless otherwise fixed by the Board of Directors, the fiscal
year of the Corporation shall be the calendar year.
Article XI
Waiver of Notice
Whenever notice is required
to be given by these Bylaws or by the Certificate of Incorporation or by law, a written waiver thereof, signed by the person or persons
entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent to notice.
Article XII
Bank Accounts, Drafts, Contracts, Etc.
Section 1. Bank
Accounts and Drafts. In addition to such bank accounts as may be authorized by the Board of Directors, the primary financial officer
or any person designated by said primary financial officer or otherwise authorized by the Board of Directors, whether or not an employee
of the Corporation, may authorize such bank accounts to be opened or maintained in the name and on behalf of the Corporation as he may
deem necessary or appropriate, payments from such bank accounts to be made upon and according to the check of the Corporation in accordance
with the written instructions of said primary financial officer, or other person so authorized.
Section 2. Contracts.
The Board of Directors may authorize any person or persons, in the name and on behalf of the Corporation, to enter into or execute and
deliver any and all deeds, bonds, mortgages, contracts and other obligations or instruments (including powers of attorney), and such authority
may be general or confined to specific instances.
Section 3. Proxies;
Powers of Attorney; Other Instruments. The Chairman, the President or any other person designated by either of them shall have the
power and authority to execute and deliver proxies, powers of attorney and other instruments on behalf of the Corporation in connection
with the rights and powers incident to the ownership of stock by the Corporation. The Chairman, the President or any other person authorized
by proxy or power of attorney executed and delivered by either of them on behalf of the Corporation may attend and vote at any meeting
of stockholders of any company in which the Corporation may hold stock, and may exercise on behalf of the Corporation any and all of the
rights and powers incident to the ownership of such stock at any such meeting, or otherwise as specified in the proxy or power of attorney
so authorizing any such person. The Board of Directors, from time to time, may confer like powers upon any other person.
Section 4. Financial
Reports. The Board of Directors may appoint the primary financial officer or other fiscal officer or any other officer to cause to
be prepared and furnished to stockholders entitled thereto any special financial notice and/or financial statement, as the case may be,
which may be required by any provision of law.
Article XIII
Amendments
The Board of Directors shall
have the power to adopt, amend or repeal these Bylaws. Bylaws adopted by the Board of Directors may be repealed or changed, and new Bylaws
made, by the stockholders, and the stockholders may prescribe that any Bylaw made by them shall not be altered, amended or repealed by
the Board of Directors.
[Remainder of the Page Intentionally Left
Blank]
v3.24.1.1.u2
Cover
|
May 30, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
May 30, 2024
|
Current Fiscal Year End Date |
--12-31
|
Entity File Number |
001-39452
|
Entity Registrant Name |
Inhibrx, Inc.
|
Entity Central Index Key |
0001739614
|
Entity Tax Identification Number |
82-4257312
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
11025 N. Torrey Pines Road
|
Entity Address, Address Line Two |
Suite 200
|
Entity Address, City or Town |
La Jolla
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
92037
|
City Area Code |
858
|
Local Phone Number |
795-4220
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Trading Symbol |
INBX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Inhibrx Biosciences (NASDAQ:INBX)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Inhibrx Biosciences (NASDAQ:INBX)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024